Vertex Pharmaceuticals Incorporated VRTX
Composite 66/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 27/100 — a moderate mark against it.
Balance-sheet strength ranks 92/100 — a strong point in its favour. Quality ranks 72/100 — a moderate point in its favour. Momentum ranks 72/100 — a moderate point in its favour.
Valuation ranks 27/100 — a moderate mark against it.
What the company does Vertex Pharmaceuticals develops and markets transformative therapies for serious diseases, notably cystic fibrosis (CF), sickle cell disease (SCD), and acute pain. Its lead products include TRIKAFTA/KAFTRIO for CF and ALYFTREK for CF patients 6 years and older. The pipeline includes gene-editing therapy CASGEVY for SCD and TDT, and early-stage candidates like VX-522 for CF and VX-264 for Type 1 Diabetes.
Key financials Vertex reports strong profitability with ROE 23.5%, ROA 11.9%, and ROCE 22.5%. Gross, operating, and net margins stand at 55.0%, 38.1%, and 35.0%, respectively. Revenue and EPS growth are 9.6% and 8.0%, with a debt/equity ratio of 0.10 and current ratio of 3.19.
Stock health The stock shows robust momentum with 3m, 6m, and 12m returns of 27.11%, 17.38%, and 41.60%, respectively. RSI(14) is elevated at 71.30, and the stock is 0.29% below its 52-week high. Sideravia scores highlight strong quality (72.4) and strength (91.5), with valuation at the 24.1th percentile.
Price vs fair value The stock trades at a **discount of 2.00%** versus the analyst mean target of 563.12. - Price is 2.00% below analyst mean target (Valuation anchor) - Valuation percentile 24.1 suggests rich pricing vs peers (Sideravia) - 3-month return of 27.11% reflects strong momentum (Momentum data) - Recent news highlights Vertex as a cash-producing stock (StockStory)
Looking forward Forward P/E of 27.47 and PEG of 2.43 indicate high expectations for future growth. The pipeline, including CASGEVY and VX-522, could drive long-term value if clinical and regulatory milestones are met. Investors should monitor execution risk in gene therapy and regulatory timelines for acute pain programs.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.